Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm for which no curative treatment currently exists. However, the discovery of abnormally activated JAK/STAT signaling pushed the clinical development of JAK1/JAK2 inhibitors and other target drugs, including inhibitors of histone deacetylases (HDACi). Areas covered: We reviewed preclinical studies and clinical trials with givinostat, a Class I and II HDACi, through PubMed research and communications to the meeting of the most important hematology associations. Expert opinion: Proof of evidence has been obtained with givinostat earlier in JAK2V617F mutated cells and then in two clinical trials in patients with PV. Treatment resulted effective in inducing hematological response, symptomatic improvement and reduction of enlarged spleen, with good tolerability. Further clinical development is required to more clearly define the role of Givinostat in the therapeutic armamentarium of PV and exploit the full activity of the drug against the myeloproliferative clone. © 2014 Informa UK, Ltd.
Givinostat for the treatment of polycythemia vera / Pieri, L., Guglielmelli, P., Finazzi, G., Vannucchi, A.M.. - In: EXPERT OPINION ON ORPHAN DRUGS. - ISSN 2167-8707. - ELETTRONICO. - 2:(2014), pp. 841-850. [10.1517/21678707.2014.934223]
Givinostat for the treatment of polycythemia vera
Pieri, Lisa;Guglielmelli, Paola;Vannucchi, Alessandro M
2014
Abstract
Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm for which no curative treatment currently exists. However, the discovery of abnormally activated JAK/STAT signaling pushed the clinical development of JAK1/JAK2 inhibitors and other target drugs, including inhibitors of histone deacetylases (HDACi). Areas covered: We reviewed preclinical studies and clinical trials with givinostat, a Class I and II HDACi, through PubMed research and communications to the meeting of the most important hematology associations. Expert opinion: Proof of evidence has been obtained with givinostat earlier in JAK2V617F mutated cells and then in two clinical trials in patients with PV. Treatment resulted effective in inducing hematological response, symptomatic improvement and reduction of enlarged spleen, with good tolerability. Further clinical development is required to more clearly define the role of Givinostat in the therapeutic armamentarium of PV and exploit the full activity of the drug against the myeloproliferative clone. © 2014 Informa UK, Ltd.| File | Dimensione | Formato | |
|---|---|---|---|
|
14688-2014.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
478.55 kB
Formato
Adobe PDF
|
478.55 kB | Adobe PDF | Richiedi una copia all'autore |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



